November 2, 2026

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Keiichi Fujiwara
Interim CFO
TEL: +81-3-5472-1125

Notice Regarding the Monthly Exercise Status of the 70th and 71st Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment

SymBio Pharmaceuticals Limited (the "Company") hereby announces the monthly exercise status for October 2026 of the 70th Stock Acquisition Rights, which were allotted to EVO FUND and issued on September 2, 2026 (the 70th Stock Acquisition Rights and the 71st Stock Acquisition Rights are collectively or individually referred to as the "Stock Acquisition Rights").

The exercise price of the 71st Stock Acquisition Rights issued to EVO FUND on September 2, 2026 has been revised in line with the exercise price of the 70th Stock Acquisition Rights described in "6. Exercise Status in the Relevant Month" below. However, under the purchase agreement with EVO FUND, the 71st Stock Acquisition Rights are structured so that they cannot be exercised until the Company gives an instruction to commence exercise. Therefore, the Company has omitted the disclosure of the monthly exercise status of the 71st Stock Acquisition Rights.

1.	Name of Stock Acquisition Rights	SymBio Pharmaceuticals Limited's 70th Stock Acquisition Rights
2.	Number of Shares Delivered in the Relevant Month	2,830,000 shares
3.	Number of Stock Acquisition Rights Exercised in the Relevant Month, and Ratio of Exercised to Total Issued Stock Acquisition Rights	28,300 rights (Ratio to total number of Stock Acquisition Rights issued 480,000: 5.9%)
4.	Number of Unexercised Stock Acquisition Rights as of the end of the previous month	437,000 rights
5.	Number of Unexercised Stock Acquisition Rights as of the End of the Relevant Month	408,700 rights

* The ratio of exercised to total issued Stock Acquisition Rights is rounded to one decimal place.

6. Exercise Status in the Relevant Month

SymBio Pharmaceuticals Limited's 70th Stock Acquisition Rights

Exercise Date	Number of Shares Delivered		Exercise Price (Yen)	Number of Stock Acquisition Rights Exercised (Rights)
	Newly Issued Shares	Transferred Treasury Shares		
October 1 (Thu)	-	－	56	-
October 2 (Fri)	50,000	－	56	500
October 5 (Mon)	-	－	56	-
October 6 (Tue)	300,000	－	55	3,000
October 7 (Wed)	-	－	56	-

October 8 (Thu)	-	-	56	-
October 9 (Fri)	50,000	-	55	500
October 13 (Tue)	50,000	-	54	500
October 14 (Wed)	50,000	-	54	500
October 15 (Thu)	80,000	-	53	800
October 16 (Fri)	600,000	-	50	6,000
October 19 (Mon)	-	-	52	-
October 20 (Tue)	460,000	-	49	4,600
October 21 (Wed)	150,000	-	49	1,500
October 22 (Thu)	-	-	50	-
October 23 (Fri)	240,000	-	48	2,400
October 26 (Mon)	220,000	-	48	2,200
October 27 (Tue)	320,000	-	47	3,200
October 28 (Wed)	140,000	-	47	1,400
October 29 (Thu)	50,000	-	47	500
October 30 (Fri)	70,000	-	46	700

* Number of shares issued as of the end of the previous month: 84,548,960 shares (including 91,394 treasury shares)

7. Status of Exercise Restrictions (Status of Compliance with Exercise Restrictions under Article 434 of the Listing Regulations)

(i) Total Number of Shares Delivered (All Series Combined)	(ii) Number of Listed Shares as of Payment Date of Issuance	(iii) Exercise Ratio Subject to Exercise Restrictions ((i) / (ii))
2,830,000 shares	80,247,210 shares	3.5%

* The exercise ratio subject to exercise restrictions is rounded to one decimal place.
* The purchase agreement for the Stock Acquisition Rights entered into between the Company and EVO FUND provides that, pursuant to Article 436, Paragraph 5, Item 4 of the Enforcement Rules for the Securities Listing Regulations established by the Tokyo Stock Exchange, the prohibition on Excess Exercise shall not apply if the exercise price is equal to or higher than the closing price on August 17, 2026, the date of the resolution for issuance.

For details concerning the Stock Acquisition Rights, please refer to the “Notice Regarding the Execution of an Unsecured Bond Facility Agreement, the Issuance of the 2nd Unsecured Straight Bonds (Private Placement), the Issuance of the 70th and 71st Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment, the Execution of a Purchase Agreement for the Stock Acquisition Rights (Commit Issue), and the Acquisition and Cancellation of the 58th, 66th, and 67th Stock Acquisition Rights” announced on August 17, 2026.